Skip to content
Ibipinabant
Ibipinabant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cannabinoid receptor 1. In addition, it is known to target cannabinoid receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIBIPINABANT
INNibipinabant
Description
Ibipinabant (SLV319, BMS-646,256) is a drug used in scientific research which acts as a potent and highly selective CB1 antagonist. It has potent anorectic effects in animals, and was researched for the treatment of obesity, although CB1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagonists. SLV330, which is a structural analogue of Ibipinabant, was reported active in animal models related to the regulation of memory, cognition, as well as in addictive behavior. An atom-efficient synthesis of ibipinabant has been reported.
Classification
Small molecule
Drug classcannabinol derivatives: CB (e.g., CB, CB2, etc.) cannabinoid receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1
Identifiers
PDB—
CAS-ID464213-10-3
RxCUI—
ChEMBL IDCHEMBL412262
ChEBI ID—
PubChem CID9826744
DrugBankDB12649
UNII IDO5CSC6WH1T (ChemIDplus, GSRS)
Target
Agency Approved
CNR1
CNR1
Organism
Homo sapiens
Gene name
CNR1
Gene synonyms
CNR
NCBI Gene ID
1268
Protein name
cannabinoid receptor 1
Protein synonyms
CANN6, cannabinoid receptor 1 (brain), central cannabinoid receptor
Uniprot ID
Q9UNN0
Mouse ortholog
Cnr1 (12801)
cannabinoid receptor 1 (Q5SF33)
Alternate
CNR2
CNR2
Organism
Homo sapiens
Gene name
CNR2
Gene synonyms
CB2A, CB2B
NCBI Gene ID
1269
Protein name
cannabinoid receptor 2
Protein synonyms
cannabinoid receptor 2 (macrophage), CX5
Uniprot ID
Q6NSY0
Mouse ortholog
Cnr2 (12802)
cannabinoid receptor 2 (Q544H5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 105 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details